Although the recent FDA approval of six new antibody–drug conjugates (ADCs) is
promising, attrition of ADCs during clinical development remains high. The inherent …

With more than 90 approved drugs by 2020, therapeutic antibodies have played a central
role in shifting the treatment landscape of many diseases, including autoimmune disorders …

Poor penetration of mAbs in solid tumors is explained, in part, by the binding site barrier
hypothesis. Following extravasation, mAbs rapidly bind cellular antigens, leading to the …

Purpose: Antibody–drug conjugate (ADC) has had a transformative effect on the treatment of
many solid tumors, yet it remains unclear how ADCs exert bystander activity in the tumor …

Computational models of disease progression have been constructed for a myriad of
pathologies. Typically, the conceptual implementation for pathology-related in silico …

Antibody drug conjugates (ADCs) have made impressive strides in the clinic in recent years
with 11 Food and Drug Administration approvals, including 6 for the treatment of patients …

Intratumoral heterogeneity is a leading cause of treatment failure resulting in tumor
recurrence. For the antibody-drug conjugate (ADC) ado-trastuzumab emtansine (T-DM1) …

Our group has developed and experimentally validated a strategy to increase antibody
penetration in solid tumors through transient inhibition of antibody-antigen binding. In prior …

A next generation multiscale quantitative systems pharmacology (QSP) model for antibody
drug conjugates (ADCs) is presented, for preclinical to clinical translation of ADC efficacy …

Abstract Antibody-Drug Conjugates (ADCs) have rapidly expanded in the clinic, with 7 new
approvals in 3 years. For solid tumors, high doses of ADCs improve tissue penetration and …